Last reviewed · How we verify
NCT03466034
The Role of Hypoxia as a Selective Pressure for TP53 Mutations
trial in Endometrial Cancer in 5 participants. Terminated before completion.
19 June 2018
Quick facts
| Lead sponsor | Institute of Cancer Research, United Kingdom |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 5 |
| Start date | 6 February 2018 |
| Primary completion | 19 June 2018 |
| Estimated completion | 30 July 2019 |
| Sites | 1 location across United Kingdom |
Conditions studied
- Endometrial Cancer — all drugs for Endometrial Cancer →
Sponsor
Institute of Cancer Research, United Kingdom
Who can join
18 and older, female only, with Endometrial Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study aims to develop scans that tell the investigators about the oxygen content of tumours using Magnetic Resonance Imaging (MRI) and seeing whether regions of low oxygen content are related to mutations in cancer genes such as TP53. MRI is a method of obtaining pictures of inside of the body that shows the appearance and structure of soft tissues. To get the information about the oxygen content of tumours, MRI is carried out while breathing 100% oxygen. The variation of oxygen supply to different regions of the tumour will help the investigators to predict tumour behavior and tumour response to treatment.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03466034
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Endometrial Cancer
Currently open trials in the same condition.
- NCT07419841 — A Phase 1 Study of the Safety and Tolerability of CTX-10726 · Phase 1 · recruiting
- NCT07382583 — Development of a Shared Decision Tool to Facilitate Uptake of the Levonorgestrel-releasing Intrauterine System for the P · recruiting
- NCT07377734 — Intrauterine Injection of Type III Collage in FST of EC/AEH · Phase 2 · recruiting
- NCT07319429 — Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification · Phase 2, PHASE3 · recruiting
- NCT07397624 — Endoscopic Suture Gastroplasty (ESG) for Treatment of Obese Patients With Endometrial Cancer · recruiting
Other Institute of Cancer Research, United Kingdom trials
Trials by the same sponsor.
- NCT06396754 — Deployment and Clinical Evaluation of an AI-powered Digital Oncology Biomarker Tool to guidE Treatment in TNBC · not yet recruiting
- NCT07391215 — 5G-PEARL: Paxalisib in Malignant Brain Tumours · Phase 1, PHASE2 · recruiting
- NCT07098819 — The eValuation of Sources of vIBRAtioN for Vibrational Shear Wave elasTography · not yet recruiting
- NCT06636526 — The i4i PRODICT® Study: Evaluation of the i4i PRODICT® Test in Different Ethnic Groups (The i4i PRODICT® Study). · recruiting
- NCT06630260 — 5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours · Phase 1, PHASE2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03466034 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Institute of Cancer Research, United Kingdom
- Last refreshed: 29 January 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03466034.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing